A5016495332- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Advanced Radiotherapy Techniques
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Radiomics and Machine Learning in Medical Imaging
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Chemotherapy-related skin toxicity
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Advances in Oncology and Radiotherapy
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Lung Cancer Research Studies
- Prostate Cancer Treatment and Research
- Nonmelanoma Skin Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Breast Implant and Reconstruction
- Neutropenia and Cancer Infections
Castle Hill Hospital
2015-2025
Queen's Medical Centre
2019-2020
Hull and East Yorkshire Hospitals NHS Trust
2012
Nottingham University Hospitals NHS Trust
2012
Nottingham City Hospital
2006-2011
Marqués de Valdecilla University Hospital
2011
Royal North Shore Hospital
2011
Royal Perth Hospital
2011
Hospital Clínico Universitario de Valencia
2011
Uppsala University Hospital
2011
BackgroundAdjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant non-inferior the 12-month regarding disease-free survival.MethodsThis study an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in UK. randomly assigned cancer,...
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether would be non-inferior to the usual treatment.The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk II and III cancer underwent central randomisation minimisation centre, choice regimen, sex, disease site, N stage, T starting dose capecitabine. were assigned...
<h3>Importance</h3> Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models human cancer, but clinical evidence is lacking. <h3>Objective</h3> To evaluate the role celecoxib as an addition to conventional therapy for women ERBB2 (formerly HER2)–negative primary cancer. <h3>Design, Setting, and Participants</h3> The Randomized European Trial (REACT) was a phase 3, randomized, double-blind study conducted 160...
3512 Background: The OPERA trial was testing the hypothesis that Contact x-ray brachytherapy (CXB) 50 kV boost will increase rectal preservation rate in early T2-T3ab adenocarcinoma. We present 3 years clinical results. Methods: Inclusion criteria were: Age > 18 years, PS: 0-1, adenocarcinoma, distal - middle rectum, cT2-T3ab cN0-N1 < 8mm staged using MRI, M0. Stratification: T vs ≥ cm diameter. Control arm (A) chemoradiotherapy (CRT) 45Gy/ 5 weeks with concurrent chemotherapy...
The timing of adjuvant chemotherapy after surgery for colorectal cancer and its association with long-term outcomes have been investigated in national cohort studies, no consensus on the optimal time from to chemotherapy.
Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, associated cumulative toxicity, characterised by chronic often irreversible neuropathy. To assess efficacy of 3-month versus 6-month cancer to compare health-related quality life cost-effectiveness durations. An international, randomised, open-label, non-inferiority, Phase III, parallel-group trial. A total 244...
The ability to deliver the planned dose and intensity of chemotherapy (the amount drug administered/unit time) is important for tumour control survival. In clinical practice, neutropenic events are main limiting factors towards achieving this aim. We assessed impact [defined as either hospital admission due febrile neutropenia (FN), delay ≥7 days or reduction ≥15% neutropenia] on (DI) in a random sample 50 patients with various solid tumours. Fifty who received systemic tumours were part...
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus usually given 6 (6 adjuvant chemotherapy in colorectal cancer. In total, 6088 patients with fully resected high-risk stage II or III cancer were followed up for 3–8 years. within-trial analysis from a UK health-care perspective presented using resource use data, quality life (EQ-5D-3L),...
4101 Background: Phase II studies reported high pathological complete response (pCR) rates and acceptable toxicity using irinotecan fluoropyrimidine chemoradiation in LARC (ISRCTN:09351447). Methods: This phase III, multicentre, open-label trial funded by Cancer Research UK, randomly assigned (1:1) patients with MRI defined threatening or involving resection margins without metastases, to pre-operative radiotherapy (RT) 45Gy/25 fractions combined either capecitabine 900mg/m 2 (CRT) 650 mg/m2...
Nonsurgical treatment with chemoradiotherapy for rectal cancer is gaining interest as it avoids total mesorectal excision (TME) surgery and stoma. The OPERA trial aims to evaluate whether dose escalation contact X-ray brachytherapy (CXB) boost improves organ preservation compared external beam radiotherapy (EBRT) boost. It has been suggested that adversely affects surgical outcomes therefore we report following TME in at 36 months.OPERA a European multicentre phase 3 (NCT02505750) which...
The standard of care for rectal cancer is radical surgery and will remain so the foreseeable future. Therefore, even early-stage small cancer, still regarded as gold 1. However, there published evidence risk in terms mortality morbidity, especially elderly or comorbid patients 2. In addition, an increase ageing population UK 3. majority are above age 65 years. Treatment options elderly, often infirm, group require careful consideration to avoid surgical harm. Moreover, many early cancers...